GSK (GSK) News
NYSE: GSKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
46.50-0.04 (-0.09%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GSK news summary
We found 24 recent headlines mentioning GSK (GSK): 2 in the past week and 20 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, GSK is down 0.09% at $46.50. The most recent story, "GSK: The Gas Pedal Is Finally Down", was published by Seeking Alpha on Oct 7, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest GSK headlines
- GSK: The Gas Pedal Is Finally DownSeeking Alpha
- State attorneys general sue RFK Jr., seeking to reinstate childhood vaccine scheduleSeeking Alpha
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic…NasdaqABBV, AZN, CBLL, CDXS
- Pre-Market Most Active for Oct 1, 2026 : SQQQ, TQQQ, INTC, MUU, TLT, GSK, NVDA, ACN, CTVA, NOK, SGOV, INFYThe NASDAQ 100 Pre-Market Indicator is up 170.98 to 30,579.48. The total Pre-Market volume is currently 137,328,934 shares traded.The following are the most active stocks for the pre-market session:…NasdaqSQQQ, TQQQ, INTC, MUU
- GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.NasdaqSNY, GSK, REGN
- Biotech Stocks Facing FDA Decision In October 2026(RTTNews) - The FDA's October decision calendar looks relatively light, with only a limited number of PDUFA dates scheduled.NasdaqGSK, INO, IRD
- Merck, Daiichi Withdraw FDA Filing for Lung Cancer TherapyMRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.NasdaqMRK, GSK
- HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors(RTTNews) - HUTCHMED (China) Limited (HCM) on Monday announced the initiation of the Phase 1a portion of a global clinical trial evaluating HMPL-A830 in patients with unresectable, advanced or…NasdaqGSK, HCM
- GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha
- GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory CareMarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination…Nasdaq
- GSK plc (GSK) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaGSK, BAC
- GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take ShapeMarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company’s growth strategy, launch priorities and cost-savings plans during a…Nasdaq
- Nyxoah CFO Landry To Step Down, Moreau Named Interim CFO; Reaffirms FY26 Guidance(RTTNews) - Nyxoah SA (NYXH.BR), a medical technology company, on Monday announced Chief Financial Officer, John Landry will step down effective October 2, 2026, to pursue another professional…NasdaqGSK, NYXH
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.NasdaqAEMD, AZN, BBNX, BIIB
- FENI, GSK, HSBC, SHEL: Large Inflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have…NasdaqFENI, GSK, HSBC, SHEL
- GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer PipelineMarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal…Nasdaq
- GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaGSK, MS
- GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyGSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.NasdaqGSK, ALDX, ACIU, PGEN
- GSK To Buy T Cell-engager For Multiple Myeloma From Chimagen Biosciences For Up To $750 Mln(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Tuesday that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager or TCE for multiple myeloma from…Nasdaq
- INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.NasdaqINCY, GSK, NVS
- GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference TranscriptSeeking Alpha
- Noteworthy ETF Outflows: FENI, GSK, UL, SHELLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have…NasdaqFENI, GSK, UL, SHEL
- GSK: Still One Of My Top Healthcare PicksSeeking Alpha
- Noteworthy ETF Inflows: FENI, UL, GSK, BTILooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have…NasdaqFENI, UL, GSK, BTI